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INTRODUCTION
he term cancer pain does not have a specific definition. In
fact, cancer patients have some of the most diverse types
of pain. Their pain can stem from any of the following: tumor infil-
tration or compression, surgery and biopsies, radiation damage to
tissues, neuropathies, ischemia, inflammation, damaged organ
structures (visceral pain), decreased mobility and arthropathies
(musculoskeletal pain), pathologic fractures. In addition some
pains are constant, others are incidental to specific movements or
intermittent. Common words used to describe pain such as
chronic pain often do not lead to understanding of the basic
mechanism of the pain. Analgesic medication or other pain treat-
ment added to the primary treatment helps to improve patient’s
experience with cancer treatment and to compliant with treatment
protocols. The World Health Organization (WHO) developed a
stepwise treatment algorithm as a guideline for the treatment of
cancer pain (Figure 1). 
This WHO analgesic ladder is composed of three basic steps: 
- Step 1: Start with non-opioid analgesic for mild pain
- Step 2: Begin using opioids (codeine, hydrocodeine) for mild to
moderate pain
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The management of pain is complex having to take into consideration patient specific
characteristics. Drug therapy should be individualized and managed based on numerous
factors. The opioid of first choice for the treatment of cancer pain is morphine, accord-
ing to the European Association for Palliative Care (2000). Transdermally administered
fentanyl is one alternative to oral morphine in the treatment of cancer pain. The transder-
mal systems are designed to deliver fentanyl at a constant rate for periods of 72 hours.
Patches with a delivery rate of 25, 50, 75 and 100 ￿g/h are available. Treatment with
transdermal fentanyl is safe and acceptable to many cancer patients. Significantly more
patients expressed a preference for transdermal fentanyl than for sustained-release oral
morphine. The global score of adverse effects was significantly lower in patients receiv-
ing transdermal fentanyl than in those receiving sustained-release oral morphine. The
transdermal fentanyl patch is as effective as oral opioids in relieving cancer-related pain,
with a safety and side effect profile equal to or better than that of oral opioids.
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Figure 1. WHO analgesic ladder (1)- Step 3: Use the more potent opioids (morphine, hydromorphine)
for moderate to severe pain
Opioids are the mainstay of cancer pain treatment; the therapeu-
tic goal for cancer pain treatment with opioids is to achieve max-
imal analgesia and minimize occurrence of adverse events.
Important principle in cancer pain management is to individualize
treatment to the patient. According to the European Association
for Palliative Care (2000) the opioid of first choice for the treat-
ment of cancer pain is morphine. This recommendation is based
on familiarity, availability and cost rather than on proven clinical
superiority (2). However, multiple opioids exist and each has
advantages and disadvantages in the clinical care of cancer pain
patients. Oral administration of opioids is preferred, but as dis-
ease progresses, it may become necessary to use other routes of
administration.
Fentanyl is a synthetic opioid agonist, which interacts primarily
with the mu-opioid receptor. Activation of mu-receptor results in
analgesia, euphoria, respiratory depression, nausea, vomiting,
decreased gastrointestinal motility (constipation), tolerance and
dependence. Fentanyl is 75 to 100 times more potent than mor-
phine, probably because fentanyl is lipophilic, allowing rapid pen-
etration of the blood-brain barrier. Fentanyl increases billiary tract
pressure and the tone of urinary tract smooth muscles. The drug
may be given intravenously, intramuscularly, intrathecally, via
mucous membranes or through the skin. Transdermally adminis-
tered fentanyl is one alternative to oral morphine in the treatment
of cancer pain (3-8).
FENTANYL TRANSDERMAL SYSTEM (DURAGESIC¤)
Pharmacokinetic properties
The low molecular weight, high potency and lipid solubility of fen-
tanyl make it suitable for delivery by the transdermal therapeutic
system (3,6,9). Transdermal administration of fentanyl was intro-
duced in United States in 1991.
The transdermal systems (figure 2) are designed to deliver fen-
tanyl at a constant rate for periods of 72 hours (3,10). 
Patches with a delivery rate of 25, 50, 75 and 100 ￿g/h are avail-
able. The amount of fentanyl delivered is proportional to the sur-
face area of the patch (3). Neither local blood flow, nor anatomi-
cal site of application seems to affect fentanyl delivery. The
absorption of fentanyl does not vary between the chest, abdomen
and thigh. A rise in body temperature to 40ßC may increase the
absorption rate by about one-third. Sweat can accumulate under
the transdermal fentanyl patch, which may alter the absorption of
fentanyl from the system into the skin. 
Fentanyl does not appear to undergo biotransformation during
transdermal permeation (11). Serum fentanyl concentrations
increase gradually following initial application, generally leveling off
between 12 and 24 hours (Table 1) (10). Thereafter, they remain
relatively constant, with some fluctuation, for the remainder of the
72-hour application period. Concentrations are highest on the first
day and decrease slightly during the second and third day.
Fentanyl is mainly metabolized by cytochrome P450(CYP)3A4
(12). The major metabolite is norfentanyl and minor metabolites
include despropionylfentanyl, hydroxyfentanyl and hydroxynor-
fentanyl. These metabolites show negligible pharmacological
activity. Unlike other opioid medications, the metabolism of fen-
tanyl is even unaffected by liver disease, and because fentanyl
does not have active metabolites, its actions are also unaffected
by renal failure. Coadministration of drugs that inhibit CYP3A4
may impair fentanyl clearance and result in increased or pro-
longed opiod effects (12). CYP3A4-inhibiting drugs are macrolide
antibiotics, azole antifungal agents, protease inhibitors; CYP3A4-
inducers are phenytoin, and carbamazepine. Patients receiving
one of these drugs in combination with transdermal fentanyl
should be carefully monitored.
Dosage and therapeutic use
Transdermal fentanyl is recommended for use in patients with
stable pain who have trouble using oral medications or who are
active and find regular oral dosing inconvenient. As with any long-
acting preparation, breakthrough medication should be provided
in addition. In 11 countries worldwide including the US, its use is
not restricted to cancer pain; the drug is also available for treat-
ment of severe chronic pain of nonmalignant origin (13).
Table 2 displays the range of 24-hour oral morphine doses that
are recommended for conversion to each transdermal fentanyl
(DURAGESIC) doses. The dosage should be individualized
according to the pain state of the patient (14). This starting dose
is recommended to minimize the potential for overdosing patients
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Figure 2. Fentanyl transdermal system
Tabele 1. Pharmacokinetic values after the first 72 hours of transdermal fentanyl
application (3)with the first dose. The conversion tables recommended in UK
and US are conservative. Less conservative table is recommend-
ed in Germany.
Geriatric, cachectic or debilitated patients should not be started
on dosages higher than 25 ￿g/h of transdermal fentanyl, unless
they are taking more than 25 mg/day oral morphine or equivalent
opioid (12). Coadministration of transdermal fentanyl and central-
ly acting depressants (sedatives, other opioids, anesthetics, hyp-
notics, phenothiazines, skeletal muscle relaxants, sedating anti-
histamines, alcohol) may result in hypoventilation, hypotension
and acute sedation.
Transdermal fentanyl is contraindicated in the management of
acute or postoperative pain and intermittent and mild pain, which
can be adequately managed with non-opioid agents (12). It
should not be administered to patients who are hypersensitive to
either fentanyl or any other component used in the system, to
patients with increased intracranial pressure, severe respiratory
failure, and severe liver or renal insufficiency. It should not be
administrated to children less than 12 years of age or patients
less than 18 years of age weighing less than 50 kg (3). 
Fentanyl in the form of the Duragesic patch should be applied
whole to an intact area of skin. It is important that patients choose
site to apply a patch where is no hair, taking care to avoid sensi-
tive areas or areas of excessive movement and prepare the appli-
cation site correctly. The area should be prepared by clipping the
any hair (not shave, shaving irritates the skin), cleaning with water
only (not soap, alcohol or lotions that might irritate the skin).
Before put a new patch on, patient should always remove and dis-
pose of the used patch properly. Application of a transdermal
patch to different sites on the body reduces the risk of adverse
reactions or toxicity. Repeated exposure of the transdermal patch
to the same area can potentially increase toxicity or adverse drug
reactions. Patient may shower, wash or bathe with the patch on.
Some people even swim while wearing it. Patch will not work
properly and may not be safe to use if it is cut or damaged.
Transdermal fentanyl patches should be warned against exposure
to external heat sources such as heat pats, electric blankets, hot
tubs, saunas and heat lamps, because heat may increase fentanyl
release from the system (12). 
Adverse effects
Global score of adverse effects was significantly lower in patients
receiving transdermal fentanyl than in those receiving sustained-
release oral morphine (3). The most serious adverse event asso-
ciated with transdermal fentanyl administration is respiratory
depression. The most frequently adverse events during fentanyl
treatment are nausea, vomiting and constipation. Adverse reac-
tions related to skin sensitivity (erythema, papules, itching,
edema) occurred in 1-2% of patients (8,9). 
Hypoventilation (respiratory rate less than 8 breaths per minute or
a PaCO2 greater than 55 mm Hg) occurred in approximately 2%
of patients during transdermal fentanyl patch treatment. The
mechanism of fentanyl-induced respiratory depression is different
from that of morphine. Mu1- receptors play an important role in
the respiratory effects of fentanyl and these effects can be pre-
vented by the mu-receptor antagonist naloxon (1,15).  No signifi-
cant respiratory depression was associated with fentanyl during
observations of patients receiving transdermal fentanyl in UK (16).
Fentanyl, like other opioids, increases the tone and decreases the
propulsive contractions of the gastrointestinal tract, diminished
billiary, pancreatic and intestinal secretions and increased ileo-
caecal and anal sphincter tone. This can result in constipation.
Constipation is less frequent with transdermal fentanyl than with
sustained-release oral morphine (3,8,17,18). In cancer patients,
the incidence of constipation was reduced by up to two-thirds
after switching from oral morphine to transdermal fentanyl (13).
The majority of patients (78%) did not experience any constipa-
tion during the study in UK (16). 
Vomiting and nausea are frequent in cancer patients and are
caused by chemotherapy or by cancer disease process. Fentanyl
like other opioids can cause vomiting and nausea. Comparative
clinical data from open trials reveal no obvious differences in the
occurrence of nausea and vomiting between transdermal fentanyl
and sustained-release oral morphine administration in patients
with cancer pain (3).
Data from randomized, clinical trial suggest that transdermal fen-
tanyl is less sedative than sustained-release oral morphine (3).
Some degree of tolerance to opioids is common in cancer
patients because these drugs are used over long periods of time.
To achieve the same level of analgesia, very high doses may be
reached causing toxicity, in particular, myoclonus.
CLINICAL STUDIES DATA
Clinical studies confirm that transdermal fentanyl is as effective
as sustained-release oral morphine in the management of cancer
pain (3). Some patients whose pain was previously uncontrolled
Cancer pain treatment
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Tabele 2. Recommended initial transdermal fentanyl dose based upon daily oral
morphine dose in US/UK and Germany (3, 12)became completely pain free.
Results from clinical study in UK show that the ratings of patients
and investigators are similar, 85% patients and 86% investigators
rated the treatment as good or excellent (16) 
In a large study, from October 1996 to February 1998 transder-
mal treatment was documented for 1005 patients (506 men and
499 women with a mean age of 60 years, range 20-92 years)
with chronic pain in Germany. Most patients suffered from cancer
pain and only 11 patients had chronic pain from non-malignant
disease. Transdermal therapy with fentanyl was safe and efficient
in this national survey (4).
Transdermal fentanyl is effective in the treatment of severe can-
cer pain, particularly when the oral route is unavailable (5,7). In
addition, the vast majority of the patients found the transdermal
system easy to use and reported as being satisfied or highly sat-
isfied with it (19). Patient acceptability is high and the cost is lower
than other methods required delivering parenteral opioids (10).
Some other studies showed that transdermal fentanyl provided
good to excellent pain relief in the majority (about 70%) of
patients (7,8,17). 
Transdermal fentanyl is equally safe, effective, with a number of
advantages over sustained-release oral morphine and other opi-
oids (7,14). The transdermal system is easy to apply, generally
requiring replacement every 72 hours. Advantages of transdermal
fentanyl include being a non-invasive dosage form, achievement
of predictable serum concentrations, high compliance, and a
potential lower rate of gastrointestinal adverse effects. Studies of
chronic pain comparing transdermal therapy with oral medica-
tions have shown that transdermal therapy improves sleep and
most importantly, results in greater improvements in quality of
life. It could be an alternative in patients who are unable to swal-
low and in patients with poor venous access. Preliminary data
indicate that it may be useful in the management of chronic non-
malignant pain (13).
Disadvantages of transdermal fentanyl are: the delay of onset of
action after application of first system (it is important that rescue
medication is readily available to patients receiving transdermally
administered fentanyl), optimal dosing may not always be possi-
ble because patch sizes are fixed, and relatively large skin areas
are required to administer higher dosages of fentanyl (3).
CONCLUSION
Transdermal administration of fentanyl offers an improvement of
pain treatment. Transdermal fentanyl is a useful alternative to
other opioid agents which are also recommended on the third
step of the WHO analgesic ladder, in the management of cancer
pain. Significantly more patients expressed a preference for trans-
dermal fentanyl than for sustained-release oral morphine. The
incidence of adverse effects was significantly lower in patients
receiving transdermal fentanyl than in those receiving sustained-
release oral morphine. Transdermal fentanyl is acceptable, safe
and effective, and may be recommended for treatment of cancer
related pain.
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